Long-Term Neuroleptic Toxicity and Mood: Blurring of Diagnostic Boundaries

  • Barry D. Jones


Exposure to neuroleptics results in long-term toxic syndromes, the most well described being tardive dyskinesia. Although schizophrenic patients are most prone to develop tardive dyskinesia because they are exposed to neuroleptics more frequently and for longer duration, evidence suggests that patients suffering from mood disorders may have a significant propensity towards developing tardive dyskinesia (1–11). The converse of this hypothesis, whether long-term neuroleptic exposure can in turn lead to symptoms resembling a mood disorder has been less extensively studied (12). In other words, can a patient, independent of diagnosis, develop long-term neuroleptic toxicity that will result in depression, lability of mood and other symptoms usually associated with a depressive syndrome. This paper will examine this hypothesis from the perspective of three types of mechanisms by which depression or depressive symptoms could develop in response to long-term neuroleptic toxicity. These three mechanisms are: 1) disfigurement with depression as a secondary reaction psychologically to the development of a tardive syndrome such as disfiguring tardive dyskinesia; 2) dysfunction with depression as a secondary effect physiologically to the development of a tardive syndrome such as respiratory dyskinesia or self-induced water intoxication syndrome (SIWIS); and 3) damage with depression, the result of a primary direct toxic effect putatively induced through damage to the frontal lobes.


Positron Emission Tomography Schizophrenic Patient Tardive Dyskinesia Corpus Striatum Water Intoxication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alpert D, Diamond F, Friedhoff A: Tremorographic studies in tardive dyskinesia. Psychopharmacol Bull 12: 5–7, 1976.PubMedGoogle Scholar
  2. 2.
    Rosenbaum AH, Niven RG, Hanson NP, et al: Tardive dyskinesia: relationship with primary affective disorder. Dis Nery Syst 38: 423–427, 1977.Google Scholar
  3. 3.
    Kane J, Struve FA, Weinhold P, et al: Strategy for the study of patients at high risk for tardive dyskinesia. Am J Psychiatry 137: 1265–1267, 1980.PubMedGoogle Scholar
  4. 4.
    Rush M, Diamond F, Alpert M: Depression as a risk factor in tardive dyskinesia. Biol Psychiatry 17: 387–392, 1982.PubMedGoogle Scholar
  5. 5.
    Hamra BJ, Nasrallah H, Clancy J, et al: Psychiatric diagnosis and risk for tardive dyskinesia. Arch Gen Psychiatry 40: 347–348, 1983.CrossRefGoogle Scholar
  6. 6.
    Yassa R, Ghadirian AM, Schwartz G: Prevalence of tardive dyskinesia in affective disorder patients. J Clin Psychiatry 44: 410–412, 1983.PubMedGoogle Scholar
  7. 7.
    Yassa R, Nair V, Schwartz G: Tardive dyskinesia and the primary psychiatric diagnosis. Psychosomatics 25: 135–138, 1984.PubMedCrossRefGoogle Scholar
  8. 8.
    Kane JM, Woerner M, Weinhold P, et al: A prospective study of tardive dyskinesia development: preliminary results. J Clin Psychopharmacol 2: 345–349, 1982.PubMedGoogle Scholar
  9. 9.
    Gardos G, Casey DE (eds): Tardive Dyskinesia and Affective Disorders. Washington, DC, American Psychiatric Press Inc, 1984.Google Scholar
  10. 10.
    Mukherjee S, Rosen AM, Giovanni C: Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 43: 342–346, 1986.PubMedCrossRefGoogle Scholar
  11. 11.
    Jones BD, Chouinard G, Annable L, et al: Factors related to tardive dyskinesia in affective disorders. 33rd Annual Meeting of the Canadian Psychiatric Association, No. 122, 1983.Google Scholar
  12. 12.
    Jones BD: Tardive dysmentia: further comments. Schizophr Bull 11: 187–189, 1985.PubMedCrossRefGoogle Scholar
  13. 13.
    Freed E: Tardive dyskinesia: subjective discomfort from psychosocial stress. South African Med J 62: 80–88, 1982.Google Scholar
  14. 14.
    Weiner WJ, Goetz CG, Nausieda PA, et al: Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med 88: 327–331, 1978.PubMedCrossRefGoogle Scholar
  15. 15.
    Chouinard G, Boisvert D, Bradwejn J: Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug. Can Med Assoc J 126: 821–822, 1982.PubMedGoogle Scholar
  16. 16.
    Burke RE, Fahn S, Jankovec J, et al: Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs. Neurology 32: 1335–1346, 1982.PubMedCrossRefGoogle Scholar
  17. 17.
    Stahl SM: Akathisia and tardive dyskinesia: changing concepts. Arch Gen Psychiatry 42: 915–917, 1985.PubMedCrossRefGoogle Scholar
  18. 18.
    Barnes TRE, Braude WM: Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 42: 874–878, 1985.PubMedCrossRefGoogle Scholar
  19. 19.
    Crane GE: Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature. Am J Psychiatry 124: 40–48, 1968.PubMedGoogle Scholar
  20. 20.
    Owens DGC, Johnstone EC, Frith CD: Spontaneous involuntary disorders of movement in neuroleptic treated and untreated chronic schizophrenics: prevalence, severity, and distributions. Arch Gen Psychiatry 39: 452–461, 1982.PubMedCrossRefGoogle Scholar
  21. 21.
    Crow TJ, Cross AJ, Johnstone EC, et al: Abnormal involuntary movements in schizophrenia: Are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J Clin Psychopharmacol 2: 236–340, 1982.CrossRefGoogle Scholar
  22. 22.
    Hunter R, Earl CJ, Thornicroft S: An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proc Roy Soc Med 57: 758–762, 1964.PubMedGoogle Scholar
  23. 23.
    Degkwitz R, Wenzel W: Persistent extrapyramidal side effects after long-term application of neuroleptics, in Neuropsychopharmacology. Edited by Brill H, Amsterdam J. International Congress Series 1967.Google Scholar
  24. 24.
    Greenberg DB, Murray GB: Hyperventilation as a variant of tardive dyskinesia. J Clin Psychiatry 42: 401–403, 1981.PubMedGoogle Scholar
  25. 25.
    Ayd FJ: Respiratory dyskinesias in patients with neuroleptic-induced extrapyramidal reactions. Int Drug Therapy Newsletter 14: 1–3, 1979.Google Scholar
  26. 26.
    Bassett A, Jones BD, Wilcox PG, et al: Objective evaluation of respiratory dyskinesia. 140th Meeting of the American Psychiatric Association, New Research Abstract 113, 1987.Google Scholar
  27. 27.
    Peterson DT, Marshall WH: Polydipsia and inappropriate secretion of antidiuretic hormone associated with hydrocephalus. Ann Intern Med 83: 675–676, 1987.CrossRefGoogle Scholar
  28. 28.
    Rao KJ, Miller M, Moses A: Water intoxication and thioridazine (letter). Ann Intern Med 82: 61–63, 1975.PubMedCrossRefGoogle Scholar
  29. 29.
    Winstead DK: Coffee consumption among psychiatric inpatients. Am J Psychiatry 133: 1447–1450, 1976.PubMedGoogle Scholar
  30. 30.
    Jones BD: Psychosis associated with water intoxication: psychogenic polydipsia or concomitant dopaminergic supersensitivity disorders? (letter). Lancet 2: 519–520, 1984.PubMedCrossRefGoogle Scholar
  31. 31.
    Dourish CT: Dopaminergic involvement in the control of drinking behaviour: a brief review. Prog Neuropsychopharmacol Biol Psychiatry 7: 487–493, 1983.PubMedCrossRefGoogle Scholar
  32. 32.
    Marshall JF, Richardson JS, Teitelbaum P: Nigrostriatal bundle damage and the lateral hypothalamic syndrome. J Comp Phys Psychol 87: 808–830, 1974.CrossRefGoogle Scholar
  33. 33.
    Shen WW, Sata LS: Hypothalamic dopamine receptor supersensitivity? A pilot study of self-induced water intoxication. Psychiatr J Univ Ottawa 8: 154–158, 1983.Google Scholar
  34. 34.
    Arieff AI, Llach F, Massry SG: Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes. Medicine 55: 121–129, 1976.PubMedCrossRefGoogle Scholar
  35. 35.
    Koczapski AB, Ibraheem S, Ashby YT, et al: Early diagnosis of water intoxication by monitoring diurnal variations in body weight. Am J Psychiatry 144: 1626, 1987.PubMedGoogle Scholar
  36. 36.
    Koczapski AB, Ashby YT, Ibraheem S, et al: Afternoon radiator-sitting syndrome (ARSS): hypothermia and early diagnosis of self-induced water intoxication. Br J Psychiatry 151: 133–134, 1987.PubMedGoogle Scholar
  37. 37.
    Illowsky BP, Kirch DG: Polydipsia and hyponatremia in psychiatric patients. Am J Psychiatry 145: 675–683, 1988.PubMedGoogle Scholar
  38. 38.
    Farkas T, Reivich M, Alavi A, et al: The application of [F] 2-deoxy-2-fluoro-D-glucose and positron emission tomography in the study of psychiatric conditions, in Cerebral Metabolism and Neural Function. Edited by Passonneau JV, Hawkins RA, Lust WD, Welsh FA. Baltimore, Williams zhaohuan Wilkins Company, 1980.Google Scholar
  39. 39.
    Ingvar DH, Franzen G: Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand 50: 425–462, 1974.PubMedCrossRefGoogle Scholar
  40. 40.
    Buchsbaum MS, Ingvar DH, Kessler R, et al: Cerebral glucography with positron tomography: use in normal subjects and in patients with schizophrenia. Arch Gen Psychiatry 39: 251–259, 1982.PubMedCrossRefGoogle Scholar
  41. 41.
    Farkas T, Wolf AP, Jaeger J, et al: Regional brain glucose metabolism in chronic schizophrenia. Arch Gen Psychiatry 41: 293–300, 1984.PubMedCrossRefGoogle Scholar
  42. 42.
    DeLisi LE, Holcomb HH, Cohen RM, et al: Positron emission tomography in schizophrenic patients with and without neuroleptic medication. J Cereb Blood Flow Metab 5: 201–206, 1985.PubMedCrossRefGoogle Scholar
  43. 43.
    DeLisi LE, Buchsbaum MS, Holcomb HH, et al: Clinical correlates of decreased anteroposterior metabolic gradients in positron emission tomography (PET) of schizophrenic patients. Am J Psychiatry 142: 78–81, 1985.PubMedGoogle Scholar
  44. 44.
    Wolkin A, Jaeger J, Brodie JD, et al: Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry 142: 564–571, 1985.PubMedGoogle Scholar
  45. 45.
    Volkow ND, Wolf AP, Van Gelder P, et al: Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia. Am J Psychiatry 144: 151–158, 1987.PubMedGoogle Scholar
  46. 46.
    Volkow ND,Brodie JD, Wolf AP, et al: Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration. J Neurol Neurosurg Psychiatry 49: 1199–1202, 1986.Google Scholar
  47. 47.
    Kling AS, Metter J, Riege WH, et al: Comparison of PET measurement of local brain glucose metabolism and CAT measurement of brain atrophy in chronic schizophrenia and depression. Am J Psychiatry 143: 175–180, 1986.PubMedGoogle Scholar
  48. 48.
    Gur RE, Resnick SM, Alavi A, et al: Regional brain function in schizophrenia, I: a positron emission tomography study. Arch Gen Psychiatry 44: 119–125, 1987.PubMedCrossRefGoogle Scholar
  49. 49.
    Gur RE, Resnick SM, Gur RC, et al: Regional brain function in schizophrenia, II: repeated evaluation with positron emission tomography. Arch Gen Psychiatry 44: 126–129, 1987.PubMedCrossRefGoogle Scholar
  50. 50.
    Weinberger DR, Berman KF, See RF: Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia, I: regional cerebral blood flow evidence. Arch Gen Psychiatry 43: 114–124, 1986.PubMedCrossRefGoogle Scholar
  51. 51.
    Weinberger DR, Berman KF, Illowsky BP: Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III: a new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 45: 609615, 1988.Google Scholar
  52. 52.
    Berman KF, Illowsky BP, Weinberger DR: Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, IV: further evidence for regional and behavioral specificity. Arch Gen Psychiatry 45: 616–622, 1988.PubMedCrossRefGoogle Scholar
  53. 53.
    Benes FM, Davidson J, Bird ED: Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiatry 43: 31–45, 1986.PubMedCrossRefGoogle Scholar
  54. 54.
    Szechtman H, Nahmias C, Garnett S, et al: Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia. Arch Gen Psychiatry 45: 523–532, 1988.PubMedCrossRefGoogle Scholar
  55. 55.
    Chouinard G, Jofnes BD, Annable L: Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 135: 1409–1410, 1978.PubMedGoogle Scholar
  56. 56.
    Chouinard G, Jones BD: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 137: 16–21, 1980.PubMedGoogle Scholar
  57. 57.
    Chouinard G, Jones B: Neuroleptic-induced supersensitivity psychosis: the ‘Hump course’ and tardive dyskinesia (letter). J Clin Psychopharmacol 2: 143–144, 1982.Google Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Barry D. Jones
    • 1
  1. 1.Department of PsychiatryUniversity of Ottawa and Royal Ottawa HospitalOttawaCanada

Personalised recommendations